Puma Biotechnology | PBYI - Selling And Administration Expenses


Puma Biotechnology reported $16.82M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Daiichi Sankyo JPY 237.75B 12.21B Sep/2026
Exelixis USD 154.56M 6.93M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Moderna USD 282M 66M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Takeda JPY 271.71B 14.8B Sep/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026